CN110295145B - Culture solution and culture method for in vitro culture of brain tumor cells - Google Patents
Culture solution and culture method for in vitro culture of brain tumor cells Download PDFInfo
- Publication number
- CN110295145B CN110295145B CN201810238925.8A CN201810238925A CN110295145B CN 110295145 B CN110295145 B CN 110295145B CN 201810238925 A CN201810238925 A CN 201810238925A CN 110295145 B CN110295145 B CN 110295145B
- Authority
- CN
- China
- Prior art keywords
- culture
- mass
- brain tumor
- tumor cells
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 68
- 208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 32
- 238000000338 in vitro Methods 0.000 title claims abstract description 24
- 238000012136 culture method Methods 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 239000001963 growth medium Substances 0.000 claims abstract description 42
- 210000002569 neuron Anatomy 0.000 claims abstract description 39
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract description 31
- 238000012258 culturing Methods 0.000 claims abstract description 15
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims abstract description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims abstract description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940054269 sodium pyruvate Drugs 0.000 claims abstract description 6
- 229960005322 streptomycin Drugs 0.000 claims abstract description 6
- 230000001228 trophic effect Effects 0.000 claims abstract description 6
- 239000012894 fetal calf serum Substances 0.000 claims abstract description 5
- 229940049954 penicillin Drugs 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 15
- 210000001638 cerebellum Anatomy 0.000 claims description 9
- 230000001079 digestive effect Effects 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 238000004114 suspension culture Methods 0.000 claims description 7
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 6
- 230000009456 molecular mechanism Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000000644 propagated effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 238000013537 high throughput screening Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000007640 basal medium Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004115 adherent culture Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000001178 neural stem cell Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 108010039918 Polylysine Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008410 smoothened signaling pathway Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100410161 Mus musculus Ptch2 gene Proteins 0.000 description 1
- 101710083394 Protein patched Proteins 0.000 description 1
- 101150085089 Ptch2 gene Proteins 0.000 description 1
- 101150046427 Sfrp1 gene Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002342 anti-penicillin Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000007990 cerebellar medulloblastoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001090 spherocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
Abstract
The invention provides a culture solution for culturing brain tumor cells in vitro, which comprises a nerve cell basic culture medium, 0.5-5% of B27 trophic factor, 0.5-5% of double-resistant-penicillin/streptomycin, 0.5-5% of glutamine, 0.5-5% of sodium pyruvate, 0.5-1.5% of fetal calf serum and 2.5-3.5 ug/mL recombinant Shh protein based on the mass of the nerve cell basic culture medium. The cells cultured by the invention can be propagated and passaged, the Shh signal channel is in an activated expression state, the tumorigenicity is not influenced, the cells can be frozen and stored at the temperature of minus 80 ℃, and the cells can be attached to the wall for differentiation, so that a unique cell model is provided for researching the molecular mechanism of the occurrence and development of the medulloblastoma and the molecular mechanism for regulating and controlling the Shh signal channel, and an important tool is provided for high-throughput screening of chemotherapeutic drugs.
Description
Technical Field
The invention belongs to the technical field of tissue cell culture, and particularly relates to a culture solution and a culture method for in-vitro culture of brain tumor cells.
Background
Medulloblastoma (MB) is the most common malignant brain tumor in children, which occurs mainly in the cerebellum and rapidly spreads into the central nervous system, and it is generally considered that MB includes at least 4 subtypes, the Wnt subtype, the Shh subtype, the third subtype and the fourth subtype. Of the 4 subtypes, Shh subtype accounts for about 30% of human medulloblastomas, and is caused by abnormal activation of Shh signaling pathway.
Astrocytes are the most widely distributed class of glial cells in the mammalian brain, and support the development and function of neurons. The role of astrocytes in brain tumors has also been elucidated to some extent in recent years: astrocytes have been reported to secrete Shh ligand in the context of neurodevelopment, adult neurogenesis, and brain injury. In medulloblastomas, Astrocytes promote the proliferation of tumor cells by secreting Shh protein (Liu, yongjiang, et. "assay protein production through hedgehog section." Cancer research 77.23(2017): 6692-6703.).
Due to the ease of culture and preservation, cell lines are widely used in cancer research. However, studies have shown that there is still a lack of an effective Shh-MB in vitro cell model. The Shh signaling pathway in cell lines currently used in either basic or preclinical studies of medulloblastoma is inactive. After knocking out the Shh pathway inhibitory protein Patched (Ptch1) by genetic means in the granular neuronal precursor cells in the mouse cerebellum, medulloblastoma was formed in the mouse brain. This model is currently widely used in basic as well as preclinical studies of medulloblastoma. However, studies have shown that the above tumor cells cultured by traditional adherent culture means are gradually inactivated in the Shh pathway in vitro, so that the tumor cells gradually stop proliferation, which brings great difficulty to the basic research of medulloblastoma and corresponding drug screening. A widely used adherent culture employs DMEM/10% FCS (Sasai, Ken, et al, "Shh pathway activity is down-regulated cultured medulloblastic cells: microorganisms for represented students," cancer research 66.8(2006): 4215-4222.).
Disclosure of Invention
The purpose of the present invention is to provide a culture solution and a culture method for in vitro cultured brain tumor cells, which are easy to culture in vitro, can be expanded and passaged, and in which the Shh signal pathway of cultured medulloblastoma cells is in an activated expression state and tumorigenicity is not affected.
In order to solve the technical problems, the invention adopts the following technical scheme:
the invention aims to provide a culture solution for culturing brain tumor cells in vitro, which comprises a nerve cell basic culture medium, B27 trophic factor with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, double-anti-penicillin/streptomycin with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, glutamine with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, sodium pyruvate with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, fetal bovine serum with the added mass of 0.5-1.5% of the mass of the nerve cell basic culture medium, and recombinant Shh (sonic hedgehog) protein. Wherein the addition amount of the recombinant Shh protein is 2.5 ug-3.5 ug added to each 1mL of the nerve cell basic culture medium.
Preferably, the addition amount of the recombinant Shh protein is 2.7 ug-3.3 ug per 1mL of the nerve cell basal medium.
Further preferably, the addition amount of the recombinant Shh protein is 2.8 ug-3.2 ug per 1mL of the neural cell basal medium.
Preferably, the addition mass of the fetal calf serum is 0.8-1.2% of the mass of the nerve cell basic culture medium.
Further preferably, the added mass of the fetal calf serum is 0.9-1.1% of the mass of the nerve cell basic culture medium.
Preferably, the addition mass of the B27 trophic factor is 1-3% of the mass of the nerve cell basic culture medium, the addition mass of the double-anti-penicillin/streptomycin is 0.5-1.5% of the mass of the nerve cell basic culture medium, the addition mass of the glutamine is 0.5-1.5% of the mass of the nerve cell basic culture medium, and the addition mass of the sodium pyruvate is 0.5-1.5% of the mass of the nerve cell basic culture medium.
More preferably, the addition mass of the B27 trophic factor is 1.5-2.5% of the mass of the nerve cell basic culture medium, the addition mass of the double-anti-penicillin/streptomycin is 0.9-1.1% of the mass of the nerve cell basic culture medium, the addition mass of the glutamine is 0.9-1.1% of the mass of the nerve cell basic culture medium, and the addition mass of the sodium pyruvate is 0.9-1.1% of the mass of the nerve cell basic culture medium.
The invention also aims to provide the application of the culture solution in the in vitro culture of the brain tumor cells.
Preferably, the brain tumor cell is a medulloblastoma cell.
Preferably, the in vitro culture method is suspension culture.
Preferably, the cell seeding density of the brain tumor cells in the culture solution is 3 × 105～5×105one/mL.
The third purpose of the invention is to provide an in vitro culture method of brain tumor cells, which inoculates the treated brain tumor cells into the culture solution for suspension culture.
Preferably, the cell seeding density is controlled to be 3 × 105～5×105one/mL.
Preferably, the brain tumor cell is a medulloblastoma cell.
Preferably, the medulloblastoma tissue extracted from the mouse cerebellum is digested for 20-40 min by using a digestive juice at 36-38 ℃, then the digestion is stopped by a pancreatin inhibitor, and then the treated brain tumor cell is obtained after filtration by a filter membrane and centrifugation, wherein each 10mL of the digestive juice contains the following components: 90U-110U of papain, 1 mg-3 mg of cysteine and 2400U-2600U of DNase.
In the present invention, the culture conditions for performing suspension culture are conventional conditions for cell culture.
The fourth purpose of the invention is to provide a tumor cell ball obtained by the in vitro culture method.
The fifth purpose of the invention is to provide a passage tumor cell, which is obtained by digesting the tumor cell sphere with digestive enzyme.
The sixth purpose of the invention is to provide the tumor cell ball cryopreservation method, wherein the tumor cell ball is cryopreserved by adopting a cryopreservation solution, the cryopreservation solution comprises serum and dimethyl sulfoxide in a mass ratio of 8-10: 1, and the cryopreservation temperature is-80 ℃.
In the present invention, cells obtained by culturing tumor cells extracted from mice in the culture medium of the present invention are referred to as primary cells; cells obtained by digesting cells cultured in a culture medium with a digestive juice and cells obtained by continuously culturing the cells are called passage cells.
The brain tumor cells cultured by the culture solution and the culture method converge into a sphere, which is called as a tumor cell sphere, so that the tumor cell sphere can survive for a long time and can be proliferated and passaged.
The invention adopts in vitro suspension culture, does not need to use polylysine (Poly-D-Lysine, PDL for short) for coating, and has simple and easy culture method.
When the culture solution and the culture method are adopted for in vitro culture, an Shh signal channel in the cell keeps an activated state, and the preclinical research of brain tumor is more convenient. Secondly, the tumor cells can be proliferated in a large amount in the culture solution and the culture method, and a large amount of cells are easily obtained for basic research and drug screening of brain tumors.
The primary cells and the passage cells cultured by the culture solution and the culture method of the invention keep tumorigenicity, and the separated tumor cell single cells or the cells digested by the tumor cell balls can grow medulloblastoma after being injected into the cerebellum of a mouse again. The method also enables us to preserve primary MB cells and passaged MB cells without changing tumorigenicity of tumor cells.
In addition, the tumor cell ball of the invention can be passaged, can be frozen and can be differentiated by attaching to the wall, and polylysine is adopted for coating during adherent differentiation.
The invention provides an important tool for researching the molecular mechanism of the occurrence and development of the medulloblastoma and screening the chemotherapeutic drugs aiming at the medulloblastoma in high flux. Meanwhile, a unique cell model is provided for researching the Shh signal channel regulation molecular mechanism.
Due to the implementation of the technical scheme, compared with the prior art, the invention has the following advantages:
the cells cultured by the culture solution and the culture method can be propagated and passaged, the Shh signal channel is in an activated expression state, the tumorigenicity is not influenced, the cells can be frozen at minus 80 ℃ and can be attached to the wall for differentiation, so that an important tool is provided for researching the molecular mechanism of the occurrence and development of the medulloblastoma and screening chemotherapeutic drugs aiming at the medulloblastoma at high flux. Meanwhile, a unique cell model is provided for researching the Shh signal channel regulation molecular mechanism.
The culture method is simple and easy to implement, and polylysine coating is not needed.
Drawings
FIG. 1 is a graph showing a comparison of the number of tumor cells per ml of culture solution after 3 days of culture with the addition of Shh protein;
FIG. 2 is a graph comparing the formation of tumor cells after 3 days of culture in different media;
FIG. 3 is a graph comparing the number of tumor cells per ml of culture medium cultured for 4days in different culture media;
FIG. 4 is a graph showing a comparison of cell viability values measured for MTT in different culture media for 2days, 3 days and 4 days;
FIG. 5 is a graph of immunocytochemical Ki67/Zic1 protein fluorescence against tumor spheres cultured for 4days in vitro;
FIG. 6 is a Tuj1 protein fluorescence plot of immunocytochemistry against tumor spheres cultured in vitro for 4 days;
FIG. 7 is a QPCR gene expression detection result chart of cultured tumor cells;
FIG. 8 is a diagram of a brain tumor of an immunodeficient mouse injected into a tumor;
FIG. 9 shows tumor cell spheres formed after passaging;
FIG. 10 shows tumor cell pellets after recovery.
Detailed Description
In order to make the present invention clearer, the present invention is further described with reference to the drawings and the embodiments, and it should be understood that the present embodiment is not intended to limit the scope of the present invention. Methods and conditions not described in detail in the present invention are conventional in the art.
Example 1
Experimental animals: conditionally knockout transgenic Mice Ptch1fl/fl Mice, Math1-Cre Mice and CB 17/SCIDMce, purchase in Jackson laboratories, all experimental animals meet SPF (Specific Pathogen Free), and all animal treatment operations are legally and effectively approved; immunodeficient Mice (CB17/SCID Mice) were implanted by intracranial injection using a mouse brain stereotaxic apparatus (KOPF, Nikon SMZ1000) and a 5ul microsampler (Shanghai Gao Pigeon).
Cell culture:
(1) and primary medulloblastoma cells are extracted from the mice brains of the conditioned knockout adult mice, the mouse cerebellar medulloblastoma tissues are digested by digestive juice, and the digestive juice components (10 ml): 100U of Papain (Papain, Worthington Biochemical, LS003126), 2mg of cysteine (L-cysteine, Sigma) and 2500U of DNase (DNase, Sigma, D4527) were digested in a water bath at 37 ℃ for 30 minutes. After termination of digestion with pancreatin inhibitor (Sigma, Roche,109878), single cell suspensions were obtained and passed through a 70um filter (Fisherbrand) and centrifuged to obtain treated medulloblastoma cells.
(2) And (2) inoculating the treated medulloblastoma cells obtained in the step (1) at a cell inoculation density of 4 × 105The inoculum size of each/mL is added into the culture solution for resuspension, and the suspension culture can be carried out in a 10cm culture dish or a six-hole plate, the culture condition is the conventional condition of cell culture (37 ℃/CO2/O2 constant temperature incubator), the culture solution does not need to be replaced or supplemented within 4days of the formation of the tumor cells, the volume of the tumor cells is not too large, the culture can be carried out for 5 days generally, and the digestion and subculture can be carried out continuously. Culture broth (i.e., NB-Shh-B27-1% FBS): the nerve cell basal medium (Neurobasal medium is abbreviated as NB, Invitrogen), 3ug of recombinant Shh protein (ab75431, abcam), B27 trophic factor (Invitrogen) accounting for 2% of the mass of the nerve cell basal medium, double anti-penicillin/streptomycin (Pen/Strep, Invitrogen) accounting for 1% of the mass of the nerve cell basal medium, glutamine (L-glutamine, Invitrogen) accounting for 1% of the mass of the nerve cell basal medium, sodium pyruvate (Na-Pyrrate, Invitrogen) accounting for 1% of the mass of the nerve cell basal medium, and Fetal Bovine serum (Fetal Bovine serum, Able, Atlanta Biologicals, S11150) accounting for 1% of the mass of the nerve cell basal medium are added to 1mL of the nerve cell basal medium.
Comparative example 1
The procedure was substantially the same as in example 1, except that no recombinant Shh protein (i.e., NB-B27-1% FBS) was added to the culture broth in example 1.
Comparative example 2
The procedure was substantially the same as in example 1, except that the fetal bovine serum was added to the culture medium in an amount of 3% by mass based on the amount of the nerve cell basal medium in example 1 (i.e., NB-Shh-B27-3% FBS).
Comparative example 3
Substantially the same as example 1, except that: the culture medium was neural Stem Cell medium (Mouse, Stem Cell Technologies) containing Proliferation Supplement 10% of the neural Stem Cell medium (Proliferation Supplement, Mouse, Stem Cell Technologies,05701), EGF (Epidermal Growth Factor, Stem Cell Technologies,78006) at 20ng/ml, FGF (Fibroblast Growth Factor, Stem Cell Technologies,78003) (i.e., NSC media).
Comparative example 4
Substantially the same as example 1, except that: the medium was DMEM (life technologies, Gibco,11995073) which is a common basal medium containing 10% fetal bovine serum (i.e., DMEM-10% FBS) by mass of the common basal medium.
Detection and data
1. Comparing the formation and cell viability of the tumor cells under the culture conditions of example 1 and comparative examples 1 to 4, wherein the formation number of the tumor cells after 3 days of culture by using the culture solution of comparative example 1 and example 1 is shown in the sequence from left to right in FIG. 1; FIG. 2 shows the numbers of spheroids and the sizes of the spheroids of the tumor cells cultured in different culture media for 3 days, wherein the upper left is the case of culturing the culture medium of example 1, the upper right is the case of culturing the culture medium of comparative example 2, the lower left is the case of culturing the culture medium of comparative example 3, and the lower right is the case of culturing the culture medium of comparative example 4; FIG. 3 is a graph showing the number of tumor cells per ml of a culture solution cultured for 4days in different culture solutions, in which four columns represent, from left to right, the culture conditions of the culture solution of example 1, the culture solution of comparative example 2, the culture solution of comparative example 3, and the culture solution of comparative example 4, respectively; FIG. 4 shows the viability values of cells cultured in different culture media for 2days, 3 days and 4days, respectively, in MTT assay, in which NB-1% FBS represents the examples1, NB-3% FBS represents the culture of comparative example 2, NSC media represents the culture of comparative example 3, and the cell viability rate of example 1 after 4days of culture is significantly higher than that of example 3. Wherein, the cell viability is measured by adopting an MTT method (MTT, trade name thiazole blue, chemical name 3- (4, 5-dimethylthiazole-2) -2, 5-diphenyl tetrazole bromide salt), and the measuring method is as follows: after the spherocytes were digested, centrifuged, counted and the cell density of each experimental group was ensured to be the same, 10ul MTT (5mg/ml) was added to each well, 3 replicates per group, 37 ℃/CO2/O2After incubation in a constant temperature incubator for 4 hours, MTT was removed by centrifugation, 100ul of dimethyl sulfoxide was added, the resulting mixture was placed in the incubator for 2 hours to sufficiently dissolve crystals, and absorbance was measured at 595nm using an enzyme reader (model No. imark 15580).
As can be seen from fig. 1 to 4, the primary MB tumor cell cultured in example 1 was most effective, while the culture in comparative examples 1 to 4 was not effective, as compared to the analysis of the number of formed tumor cells and cell viability.
2. Cultured for 4days according to the method of example 1, immunocytochemistry and cytobiology analysis: a first antibody: ki67(1:500, Abcam), Tuj 1(1:500, Abcam), Zic1(1:500, Abcam); secondary antibody: goat anti-Mouse Alexa Fluor-594anti-Mouse IgG (1:200), goat anti-Rabbit Alexa Fluor-594anti-Rabbit IgG (1:200), stained using conventional SP immunocytochemistry, and all immunofluorescent cell samples were photographed using a fluorescence inverted Microscope (Nikon Eclipse Ti Microscope), and the results are shown in FIGS. 5 and 6. From fig. 5 and fig. 6, it can be seen that the cells in the tumor sphere express the cell proliferation marker Ki67 protein, the marker Zic1 protein expressing cerebellar cells and the marker Tuj1 protein expressing neurons. Thus, the tumor cell balls in this culture condition still have their original neural properties and proliferation properties.
3. Culturing for 2 to 4days according to the method of example 1, and culturing for 1 to 2days according to a traditional adherent culture method, wherein the traditional adherent culture method comprises the following steps: PDL was first coated onto the well plates, then NB-Shh-B27/1% FBS medium was resuspended and placed at 37 ℃/CO2/O2Culturing in a constant temperature incubator. In order to eliminate the possible influence of the Shh protein and the serum on the Shh signal channel in the experiment, the experiment is carried outThe culture solution under homospheronization culture, namely NB-Shh-B27/1% FBS, is adopted as the nutrient solution, Shh protein and FBS are added, and then the activation condition of the GLi1/Ptch2/Sfrp1 gene in the Shh signal channel is detected by a real-time fluorescence quantification-PCR (QPCR) method.
Real-time fluorescent quantitative PCR: RNA in cell samples was extracted by lysis with Trizol reagent, followed by reverse transcription to synthesize cDNA according to standard procedures provided in the reverse transcription kit Qiagen RT kit, and quantitative PCR detection analysis (BIORAD iCycler iQ system).
Generally, the Shh signal pathway of a just-extracted primary tumor cell is in an activated state, compared with an adherent differentiated tumor cell and a just-extracted primary tumor cell, the expression of Shh signal pathway target genes is obviously reduced after the traditional adherent culture of the primary tumor cell is cultured for 2days, the Shh signal pathway is gradually inactivated, and the expression of the three genes is still maintained at a higher level when the tumor cell is cultured in vitro for 4days, which indicates that the Shh signal pathway is in an activated state, and the result is shown in fig. 7, wherein 0hr is the gene activation condition of the just-extracted primary tumor cell; 1day adhesive culture is the gene activation condition of traditional adherent culture for 1 day; 2days for traditional adherent culture, wherein the gene activation condition is 2days for traditional adherent culture; 2days cultivation for 2days gene activation as in example 1; the 4days sphere culture refers to the gene activation in the 4days culture in example 1.
4. After 4days of culture according to the method of example 1, they were divided into two groups, the first group was injected directly into the cerebellum of CB17-SCID mice without treatment, and the second group was injected into the cerebellum of CB17-SCID mice after digesting into single cells using the digestive enzyme Accutase. It can be seen that the injection of two groups of cells into the mouse cerebellum all produce medulloblastoma, which indicates that the medulloblastoma cultured by the method has tumorigenicity, and the culture mode of the tumor cell can be used for preclinical research of therapeutic drugs such as proliferation inhibition and the like. The results are shown in fig. 8, the brain tumor map of the injection tumor (left one is intracranial tumor brain map of the injection two-week immunodeficient mice, and hematoxylin-eosin (HE) stained section map of the right two-week tumor cerebellum) and table 1.
TABLE 1 statistics of tumor formation
| Class of injected cells | Number of long tumor mice (one)/total amount of mice (one) | Tumor formation rate (%) |
| Tumor |
3/3 | 100 |
| Digested |
3/3 | 100 |
5. Using a digestive enzyme: accutase can be used for subculturing after digesting the tumor sphere cells into single cells, and FIG. 9 shows the generation 2 tumor sphere cells formed after digesting and subculturing the 4-day cultured tumor sphere cells.
6. Using a freezing medium: 90% serum/10% dimethyl sulfoxide, the tumor cell can be frozen at-80 ℃ for 4days, fig. 10 shows that the tumor cell can be successfully recovered after being frozen at-80 ℃ for 4days, and the tumor cell growing for the next day shows that the tumor cell has the capability of low-temperature preservation, while the traditional primary culture medulloblastoma cell can not be frozen at low temperature, which is another great advantage of primary spheroidization culture.
Claims (8)
1. A culture solution for culturing brain tumor cells in vitro is characterized in that: the culture solution comprises a nerve cell basic culture medium, B27 trophic factors with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, bis-anti-penicillin/streptomycin with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, glutamine with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, sodium pyruvate with the added mass of 0.5-5% of the mass of the nerve cell basic culture medium, fetal calf serum with the added mass of 0.5-1.5% of the mass of the nerve cell basic culture medium, and recombinant Shh protein; wherein the addition amount of the recombinant Shh protein is 2.5-3.5 mu g per 1mL of the nerve cell basic culture medium.
2. The culture solution for in vitro culturing of brain tumor cells according to claim 1, wherein: the addition amount of the recombinant Shh protein is 2.8-3.2 mu g of the recombinant Shh protein added into every 1mL of the nerve cell basic culture medium.
3. The culture solution for in vitro culturing of brain tumor cells according to claim 1, wherein: the addition mass of the fetal calf serum is 0.8-1.2% of the mass of the nerve cell basic culture medium.
4. Use of a culture solution according to any one of claims 1 to 3 for the in vitro culture of brain tumor cells; the brain tumor cell is a medulloblastoma cell.
5. Use according to claim 4, characterized in that: the in vitro culture method is suspension culture.
6. The use of claim 4, wherein said brain tumor cells are seeded in said culture medium at a cell seeding density of 3 × 105~5×105one/mL.
7. An in vitro culture method of brain tumor cells, which is characterized in that: inoculating the treated brain tumor cells into the culture solution of any one of claims 1 to 3 for suspension culture; the brain tumor cell is a medulloblastoma cell.
8. The method for culturing brain tumor cells according to claim 7, wherein: the preparation method of the treated brain tumor cell comprises the following steps: digesting a medulloblastoma tissue extracted from a mouse cerebellum for 20-40 min at 36-38 ℃ by using a digestive juice, stopping digestion by using a pancreatin inhibitor, filtering by using a filter membrane, and centrifuging to obtain the treated brain tumor cells, wherein each 10mL of the digestive juice contains the following components: 90-110U of papain, 1-3 mg of cysteine and 2400-2600U of DNase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810238925.8A CN110295145B (en) | 2018-03-22 | 2018-03-22 | Culture solution and culture method for in vitro culture of brain tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810238925.8A CN110295145B (en) | 2018-03-22 | 2018-03-22 | Culture solution and culture method for in vitro culture of brain tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110295145A CN110295145A (en) | 2019-10-01 |
| CN110295145B true CN110295145B (en) | 2020-10-16 |
Family
ID=68025584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810238925.8A Expired - Fee Related CN110295145B (en) | 2018-03-22 | 2018-03-22 | Culture solution and culture method for in vitro culture of brain tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110295145B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112760286B (en) * | 2019-11-04 | 2022-12-02 | 北京基石生命科技有限公司 | Method for culturing primary cells of brain tumor solid tumor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014011881A2 (en) * | 2012-07-11 | 2014-01-16 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| WO2017160234A1 (en) * | 2016-03-14 | 2017-09-21 | Agency For Science, Technology And Research | Generation of midbrain-specific organoids from human pluripotent stem cells |
-
2018
- 2018-03-22 CN CN201810238925.8A patent/CN110295145B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014011881A2 (en) * | 2012-07-11 | 2014-01-16 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| WO2017160234A1 (en) * | 2016-03-14 | 2017-09-21 | Agency For Science, Technology And Research | Generation of midbrain-specific organoids from human pluripotent stem cells |
Non-Patent Citations (1)
| Title |
|---|
| Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog;Robert J. Wechsler-Reya等;《Neuron》;19990131;第22卷(第1期);第103-114页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110295145A (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104894060B (en) | Inducing somatic transdifferentiation is the method and its application of neural stem cell | |
| CA2489206C (en) | Method for producing neural cell | |
| CN112626023B (en) | Spinal cord olig2+ nerve progenitor cell induction and self-renewal culture system, induction method and application | |
| US20120219535A1 (en) | Cranial neural crest stem cells and culture condition that supports their growth | |
| CN105392881A (en) | Small molecule based conversion of somatic cells into neural crest cells | |
| Zhang et al. | Actin alpha 2 (ACTA2) downregulation inhibits neural stem cell migration through rho GTPase activation | |
| CN110295145B (en) | Culture solution and culture method for in vitro culture of brain tumor cells | |
| AU2011265956B2 (en) | Method for differentiating human neural progenitor cells into dopaminergic neurons, and medium for differentiation thereof | |
| CN108070558B (en) | Preparation method of clinical-grade neural stem cells | |
| CN111635889B (en) | Compositions and methods for reprogramming human astrocytes into neurons or brain-like organs | |
| CN101294146B (en) | System for inducing nerve stem cell differentiation and inducing method thereof | |
| CN115404218A (en) | 3D human brain organoid culture method containing glial cells | |
| A Baghbaderani et al. | A review of bioreactor protocols for human neural precursor cell expansion in preparation for clinical trials | |
| CN111803497A (en) | Application of lercanidipine drugs in preparation of drugs for treating human glioma | |
| CN103305458A (en) | Method for inducing cholinergic neurons from pluripotent stem cells | |
| CN109576308A (en) | A kind of method and its application improving human stem cells source hepatic lineage function of detoxification | |
| CN116445410A (en) | Method for regulating and controlling differentiation of neural stem cells and biological product used by method | |
| CN110536962A (en) | The method for efficiently separating the neural stem cell in human brain tissue source | |
| CN101824398B (en) | Method for co-culturing, inducing and differentiating dopaminergic neuron by human amniotic epithelial cells and neural stem cells | |
| WO2016060520A1 (en) | Composition for differentiating stem cells into neural precursor cells and method using same | |
| CN114958767B (en) | Preparation method of neural stem cell preparation constructed based on hiPSC cells | |
| CN107177617A (en) | A kind of LV HDAC1 of targeted silent HDAC1 genesshRNASlow virus synthetic method and application | |
| KR20140130593A (en) | Method for proliferating neuronal progenitor cells and composition for treating nervous diseases comprising the neuronal progenitor cells | |
| Jiao et al. | Effect of VEGF on neural differentiation of human embryonic stem cells in vitro | |
| CN112980792B (en) | Chemical culture system and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201016 |